Linked Life Data

20142051

Source:http://linkedlifedata.com/resource/pubmed/id/20142051

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-9
pubmed:abstractText
The utilization of androgen deprivation therapy in prostate cancer has evolved over time. Unquestionably considered first line treatment in metastatic cancers or in case of lymph node involvement, it is increasingly used in locally advanced and high-risk cancers, combined with radiation therapy. However, the practical modalities of treatment are still controversial (neoadjuvant, concomitant/adjuvant) and should be discussed on a case-by-case basis, taking into account tumor stage and risk level, which depends mainly on Gleason score and PSA levels and kinetics. Hormone therapy is also indicated in case of systemic relapse, especially if PSA doubling time is less than 12 months. LHRH agonists have become the standard care; antiandrogens can be added at the beginning of the LHRH agonist therapy to obtain a complete androgen blockade. Intermittent androgen deprivation therapy has recently proved efficacious and might be more widely used in the future, provided that strict prescription and follow-up recommendations are clearly established.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1166-7087
pubmed:author
pubmed:copyrightInfo
(c) 2009 Elsevier Masson SAS. All rights reserved.
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
109-15
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[First line indications for hormonal therapy in prostate cancer].
pubmed:affiliation
Clinique d'urologie, université Paris VII - Denis-Diderot, hôpital Bichat Claude-Bernard, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
pubmed:publicationType
Journal Article, English Abstract